Amy Blake, NP
Nurse Practitioner · Detroit, MINPI 1467062950
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by GSK at 43.1% of the total. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $195.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$7K
- Alnylam Pharmaceuticals Inc.$7K
- Beigene USA, Inc.$624
- Johnson & Johnson$563
- Adaptive Biotechnologies Corporation$471
- Amgen$352
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,87011%
- Speaking & faculty fees$8,19048%
- Travel & lodging$2,43814%
- Food & beverage$4,60527%
- Education$871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 12 | $7,405 |
| Alnylam Pharmaceuticals Inc. | 38 | $6,529 |
| Beigene USA, Inc. | 6 | $624 |
| Johnson & Johnson | 5 | $563 |
| Adaptive Biotechnologies Corporation | 4 | $471 |
| Amgen | 4 | $352 |
| Pfizer | 3 | $254 |
| E.r. Squibb & Sons, L.L.C. | 2 | $249 |
| Genentech USA, Inc. | 1 | $139 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $94 |
| Lilly USA, LLC | 1 | $87 |
| Novartis | 1 | $79 |
| Bristol Myers Squibb | 3 | $68 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Seagen Inc. | 1 | $39 |
| Gilead | 1 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,189 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 97 | $2,198,632 |
| RevlimidLenalidomide | 49 | $761,018 |
| Lenalidomide | 42 | $628,364 |
| VyndamaxTafamidis | 24 | $581,581 |
| VenclextaVenetoclax | 14 | $241,639 |
| NinlaroIxazomib Citrate | 16 | $188,071 |
| SprycelDasatinib | 11 | $172,279 |
| ZarxioFilgrastim-Sndz | 17 | $14,241 |
| Acyclovir | 74 | $2,227 |
| Colestipol Hcl | 13 | $1,156 |
| Oxycodone Hcl | 16 | $519 |
| Gabapentin | 16 | $513 |
| Potassium Chloride | 13 | $487 |
| Dexamethasone | 30 | $299 |
| Lorazepam | 11 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $249 | $2,370,910108 claims |
| Bristol Myers SquibbRevlimid | $68 | $761,01849 claims |
| PfizerVyndamax | $254 | $581,58124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $94 | $188,07116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Detroit
- Davida KrugerDetroit$739K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Rosanne OsoskiDetroit$25K
- Tanya McCauleyDetroit$15K
- Linda ManninoDetroit$12K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Abubakir BabanDearborn$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.